Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGB | P11216 | 8/20 | 0.40 |
| ▸ | PYGL | P06737 | 3/20 | 0.39 |
| ▸ | PYGM | P11217 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GBA1 | P04062 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 2/20 | 0.33 |
| ▸ | SLC5A2 | P31639 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9504070 | 1.00 | PYGB (0.40) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL667997 | 0.88 | PYGB (0.37) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL11433426 | 0.86 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL11434576 | 0.86 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL11435563 | 0.86 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL11439545 | 0.86 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL11439549 | 0.86 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL11434569 | 0.86 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL11442332 | 0.86 | PYGB (0.36) | PYGBPYGLPYGMMEN1KMT2A | |
| SCHEMBL13276647 | 0.85 | PYGB (0.41) | PYGBPYGLPYGMMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210244812-A1 | COMPOSITIONS AND METHODS CONCERNING IMMUNE TOLERANCE | THE UNIVERSITY OF CHICAGO (US) | 2021-08-12 | — | — | US | disclosed |
| CN-112384239-A | Compositions and methods for affecting immune tolerance | 芝加哥大学 | 2021-02-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210244812-A1 | COMPOSITIONS AND METHODS CONCERNING IMMUNE TOLERANCE | CD74, HLA-DRB1, MICA | PYGB 3964/4885PYGL 1929/4885PYGM 2861/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.